Allergan Strikes Back at Valeant

Let the argument between the bean counters at Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and research and development scientists at Allergan, Inc. (NYSE:AGN) begin! Questioning research and development cuts After Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) launched a $46 billion cash and stock bid to roll-up Allergan, Inc. (NYSE:AGN) , today Allergan struck back, attacking Valeant’s core business model. Valeant has acquired other research and development heavy medical related firms with a strategy to cut expenses, notably in research and new product development.  Allergan, on the other hand, defends scientific research at the firm, saying in a press release cutting the…